Yak Retsat Mutation Offers New Path for MS Myelin Repair

Genetic Adaptation and Myelin Repair Mechanism

Genetic adaptations in high-altitude species like yaks and Tibetan antelopes involve a mutation in the Retsat gene, which supports neural function in low-oxygen environments. This mutation, absent in lowland species, enables survival in chronic hypoxia. Researchers at Shanghai Jiao Tong University, led by Liang Zhang, explored its potential to address myelin damage linked to multiple sclerosis (MS). Published in Neuron, the study connects the mutation to enhanced survival in high-altitude regions like the Tibetan Plateau, where elevations average 14,700 feet. A separate study from the University of California, San Diego identified a genetic adaptation in yaks related to cold-shock protein production, which may also contribute to their resilience in extreme conditions.

The Retsat mutation facilitates the conversion of vitamin A-related molecules into metabolites that stimulate myelin production. Specifically, it enhances enzymatic activity to transform vitamin A into ATDR and subsequently into ATDRA, which triggers oligodendrocyte maturation—cells responsible for myelin synthesis. Myelin, a fatty sheath around nerve fibers, ensures efficient signal transmission. In MS, immune attacks on myelin cause neurological deficits. The study indicates that the Retsat mutation may activate a pathway to repair myelin damage by increasing ATDR levels, promoting oligodendrocyte maturation. Insufficient oxygen during brain development can disrupt myelination, leading to conditions like cerebral palsy in newborns.

Experimental Findings in Animal Models

Experiments by Zhang’s team showed young mice exposed to low-oxygen conditions (equivalent to 5,800-meter altitudes) with the Retsat mutation exhibited improved cognitive and behavioral outcomes compared to controls. These mice had higher myelin levels and better performance in memory and social behavior tests. In adult mice with MS-like brain damage, the mutation enabled faster and more complete myelin regeneration. Injections of ATDR and ATDRA reduced hypoxia-induced myelin damage, while ATDR administration to MS-like mice improved motor function. These findings suggest the Retsat pathway could repair myelin in humans.

Current Therapies and the Promise of the Retsat Pathway

Current MS therapies focus on suppressing immune activity to slow disease progression, but repairing myelin damage remains challenging. The Retsat pathway offers a novel approach by leveraging naturally occurring molecules like ATDR. Researchers note that ATDR is already present in the human body, potentially reducing side effects compared to synthetic drugs. However, earlier attempts to boost mature oligodendrocyte levels using similar mechanisms caused severe side effects, prompting a pause in such research. Zhang emphasizes the need for precise dosing, as ATDR has multiple functions and could pose risks if misused.

Future Implications and Research Directions

Translating these findings to humans requires rigorous clinical trials, with the study’s authors highlighting the need for preclinical research on pharmacokinetics and long-term safety to assess clinical viability. The broader implications extend beyond MS, as myelin damage is linked to conditions like cerebral palsy, cerebral small vessel disease, and vascular dementia. Researchers are exploring gene therapy to introduce the Retsat variant into human cells, which could revolutionize treatments for neurodegenerative disorders. Zhang notes that evolutionary adaptations like the Retsat mutation may hold the key to developing therapies that repair damaged neural tissues using the body’s own mechanisms. The research was supported by the National Science and Technology Major Project, underscoring its potential for translational medicine.